Trending...
- P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
- Tuckwell Machinery Launches New Range of Woodworking Machinery
- A Brave Little Hero with Four Paws
Vulnerable elderly residents face serious risks and premature death from antipsychotics.
LOS ANGELES - PrAtlas -- By CCHR International
The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, warns that vulnerable elderly residents in some U.S. nursing homes continue to face serious risks of premature death from antipsychotics. Some facilities and their prescribers evade meaningful accountability, and penalties remain too weak to deter the abuse.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) recently issued two reports examining psychotropic drugging in nursing homes. In a review of 40 Centers for Medicare and Medicaid Services (CMS) inspections, the OIG found that some facilities routinely administered antipsychotics—drugs not Food and Drug Administration (FDA)-approved for dementia and linked to increased mortality—to control resident behavior, while frequently failing to implement required safeguards.[1]
"The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others," the OIG stated. The reports also addressed how some nursing homes misdiagnose residents with "schizophrenia" to bypass accountability and artificially improve public quality ratings. The OIG recommended that CMS strengthen oversight, closely monitor schizophrenia diagnosis rates, target high-risk facilities, and ensure residents and families receive clear information about antipsychotic use.
CCHR's international president, Jan Eastgate, responded: "For decades, this abuse has been reported, with promises of increased oversight. These latest government reports reinforce that our elderly are being misdiagnosed and plied with debilitating antipsychotics." Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate, she said.
More on PrAtlas
In 2011, OIG Inspector General Daniel Levinson declared: "Government, taxpayers, nursing home residents, as well as their families and caregivers, should be outraged—and seek solutions."[2] In 2023, HHS had identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, but the agency did not impose substantial financial penalties at the time.[2]
Antipsychotics carry well-documented dangers for the elderly. In 2005, the Food and Drug Administration (FDA) issued a black-box warning for their use in dementia patients due to elevated death risks.[3] In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs.[4] A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.[5]
The problem dates back decades:
1987: Congress passed the Omnibus Reconciliation Act, including the Nursing Home Reform Act, intended to curb chemical restraints; the practice shifted to medication-based "chemical restraints."[6]
2007: Sen. Chuck Grassley called for an OIG review of antipsychotic use and marketing in nursing homes.[7]
2012–2015: CMS's National Partnership to Improve Dementia Care reduced prescribing somewhat, but schizophrenia diagnoses rose sharply, undermining progress.[8]
2019–2020: Roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the crisis as "one of patient harm, inadequate oversight, and insufficient staffing."[9]
More on PrAtlas
Eastgate concluded, "This continued drugging despite repeated investigations needs to change. Accountability is vital because our seniors deserve compassion and safety, not sedation and premature death."
CCHR urges Congress, CMS, and state authorities to enact immediate, enforceable protections—including strong penalties on any prescribers and facilities engaged in such practices—and to prioritize non-drug alternatives for behavioral care in nursing homes.
CCHR is a nonprofit mental health watchdog, established by the Church of Scientology and Professor of Psychiatry, Thomas Szasz, M.D., dedicated to eradicating abuses committed under the guise of mental health care. Since 1969, CCHR has helped secure hundreds of laws protecting individuals from coercive psychiatric practices.
Sources:
[1] Nursing Homes' Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents, OIG, 16 Mar. 2026, oig.hhs.gov/reports/all/2026/nursing-homes-inappropriate-use-of-antipsychotic-drugs-poses-a-risk-to-residents/
[2] "Overmedication of Nursing Home Patients Troubling," OIG, 1 June 2011
[3] "Nursing Homes Under Investigation for Abuse of Antipsychotics," Newsmax.com, 18 Jan. 2023
[4] Jeanne Lenzer, "FDA warns about using antipsychotic drugs for dementia," BMJ, 23 Apr. 2005,
[5] Testimony by Dr. David Graham, House Hearing, 110th Congress – The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply General, 13 Feb. 2007, p. 66
[6] "Antipsychotics Pose New Risks for People With Dementia," AARP, 24 Apr. 2024, Updated 27 Jan. 2026
[7] P S Masand, "Side effects of antipsychotics in the elderly "J Clin Psychiatry, 2000
[8] "Under-Enforced and Over-Prescribed: The Antipsychotic Drug Epidemic Ravaging America's Nursing Homes." Report of the Committee on Ways and Means Majority U.S. House of Representatives, July 2020, p. 9
[9] "Long-Term Trends of Psychotropic Drug Use in Nursing Homes," Health and Human Services Office of the Inspector General, 11 Nov. 2022
The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, warns that vulnerable elderly residents in some U.S. nursing homes continue to face serious risks of premature death from antipsychotics. Some facilities and their prescribers evade meaningful accountability, and penalties remain too weak to deter the abuse.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) recently issued two reports examining psychotropic drugging in nursing homes. In a review of 40 Centers for Medicare and Medicaid Services (CMS) inspections, the OIG found that some facilities routinely administered antipsychotics—drugs not Food and Drug Administration (FDA)-approved for dementia and linked to increased mortality—to control resident behavior, while frequently failing to implement required safeguards.[1]
"The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others," the OIG stated. The reports also addressed how some nursing homes misdiagnose residents with "schizophrenia" to bypass accountability and artificially improve public quality ratings. The OIG recommended that CMS strengthen oversight, closely monitor schizophrenia diagnosis rates, target high-risk facilities, and ensure residents and families receive clear information about antipsychotic use.
CCHR's international president, Jan Eastgate, responded: "For decades, this abuse has been reported, with promises of increased oversight. These latest government reports reinforce that our elderly are being misdiagnosed and plied with debilitating antipsychotics." Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate, she said.
More on PrAtlas
- Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
- CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
- Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
- New analysis reveals second job workers keep just 80p in every pound they earn
- NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
In 2011, OIG Inspector General Daniel Levinson declared: "Government, taxpayers, nursing home residents, as well as their families and caregivers, should be outraged—and seek solutions."[2] In 2023, HHS had identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, but the agency did not impose substantial financial penalties at the time.[2]
Antipsychotics carry well-documented dangers for the elderly. In 2005, the Food and Drug Administration (FDA) issued a black-box warning for their use in dementia patients due to elevated death risks.[3] In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs.[4] A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.[5]
The problem dates back decades:
1987: Congress passed the Omnibus Reconciliation Act, including the Nursing Home Reform Act, intended to curb chemical restraints; the practice shifted to medication-based "chemical restraints."[6]
2007: Sen. Chuck Grassley called for an OIG review of antipsychotic use and marketing in nursing homes.[7]
2012–2015: CMS's National Partnership to Improve Dementia Care reduced prescribing somewhat, but schizophrenia diagnoses rose sharply, undermining progress.[8]
2019–2020: Roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the crisis as "one of patient harm, inadequate oversight, and insufficient staffing."[9]
More on PrAtlas
- A Foundational Claim in Human Secrecy Goes Public
- Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
- Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
- Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
- Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
Eastgate concluded, "This continued drugging despite repeated investigations needs to change. Accountability is vital because our seniors deserve compassion and safety, not sedation and premature death."
CCHR urges Congress, CMS, and state authorities to enact immediate, enforceable protections—including strong penalties on any prescribers and facilities engaged in such practices—and to prioritize non-drug alternatives for behavioral care in nursing homes.
CCHR is a nonprofit mental health watchdog, established by the Church of Scientology and Professor of Psychiatry, Thomas Szasz, M.D., dedicated to eradicating abuses committed under the guise of mental health care. Since 1969, CCHR has helped secure hundreds of laws protecting individuals from coercive psychiatric practices.
Sources:
[1] Nursing Homes' Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents, OIG, 16 Mar. 2026, oig.hhs.gov/reports/all/2026/nursing-homes-inappropriate-use-of-antipsychotic-drugs-poses-a-risk-to-residents/
[2] "Overmedication of Nursing Home Patients Troubling," OIG, 1 June 2011
[3] "Nursing Homes Under Investigation for Abuse of Antipsychotics," Newsmax.com, 18 Jan. 2023
[4] Jeanne Lenzer, "FDA warns about using antipsychotic drugs for dementia," BMJ, 23 Apr. 2005,
[5] Testimony by Dr. David Graham, House Hearing, 110th Congress – The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply General, 13 Feb. 2007, p. 66
[6] "Antipsychotics Pose New Risks for People With Dementia," AARP, 24 Apr. 2024, Updated 27 Jan. 2026
[7] P S Masand, "Side effects of antipsychotics in the elderly "J Clin Psychiatry, 2000
[8] "Under-Enforced and Over-Prescribed: The Antipsychotic Drug Epidemic Ravaging America's Nursing Homes." Report of the Committee on Ways and Means Majority U.S. House of Representatives, July 2020, p. 9
[9] "Long-Term Trends of Psychotropic Drug Use in Nursing Homes," Health and Human Services Office of the Inspector General, 11 Nov. 2022
Source: Citizens Commission on Human Rights International
Filed Under: Consumer, Medical, Health, Government, Science, Citizens Commission On Human Rights, CCHR International
0 Comments
Latest on PrAtlas
- P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
- Tuckwell Machinery Launches New Range of Woodworking Machinery
- A Brave Little Hero with Four Paws
- Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation
- Ecuador Freedom Launches First Scheduled Motorcycle Tour of Northern Peru's Lost Kingdoms
- Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
- Neuro Recovery Institute Showcases Emerging Immersive Neuro-Rehabilitation Technology at Clinical Innovation Open House
- Community, Conservation & Waterwise Inspiration Bloom on June 6
- Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
- Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
- CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
- Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
- Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
- AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
- UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
- Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
- TechHouse Earns Highly Selective Microsoft Support Badge
- J&J Exterminating Celebrates 65th Anniversary and Unveils Strategic Vision at Annual Team Meeting
- Tru by Hilton El Paso Airport Opens to Guests
- Zenylitics Announces Leadership Transition to Continue Accelerated Growth